Upadacitinib for treating giant cell arteritis [ID6299]

Draft guidance

Draft guidance (downloadable version) (PDF 242 KB)

Draft guidance (online commenting)

Committee papers (PDF 10.96 MB)

Public committee slides (PDF 1.22 MB)

Committee meeting: 1

Final scope (PDF 91 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 352 KB)

Equality impact assessment (scoping) (PDF 51 KB)

Draft scope post referral (PDF 166 KB)

Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.  In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. 

Please note that following on from a request received from the company, this appraisal has been scheduled back into the work programme. The appraisal is now anticipated to begin in mid-March 2025 when we will write to you about how you can get involved.

The final stakeholder list was updated in May 2025 to include a relevant provisional consultee.

For operational reasons, the first committee meeting discussion of this appraisal has been rescheduled for Wednesday 10 December 2025.